{Reference Type}: Journal Article
{Title}: Mycobacteriophages: therapeutic approach for mycobacterial infections.
{Author}: Raman SK;Siva Reddy DV;Jain V;Bajpai U;Misra A;Singh AK;
{Journal}: Drug Discov Today
{Volume}: 29
{Issue}: 7
{Year}: 2024 Jul 1
{Factor}: 8.369
{DOI}: 10.1016/j.drudis.2024.104049
{Abstract}: Tuberculosis (TB) is a significant global health threat, and cases of infection with non-tuberculous mycobacteria (NTM) causing lung disease (NTM-LD) are rising. Bacteriophages and their gene products have garnered interest as potential therapeutic options for bacterial infections. Here, we have compiled information on bacteriophages and their products that can kill Mycobacterium tuberculosis or NTM. We summarize the mechanisms whereby viable phages can access macrophage-resident bacteria and not elicit immune responses, review methodologies of pharmaceutical product development containing mycobacteriophages and their gene products, mainly lysins, in the context of drug regulatory requirements and we discuss industrially relevant methods for producing pharmaceutical products comprising mycobacteriophages, emphasizing delivery of mycobacteriophages to the lungs. We conclude with an outline of some recent case studies on mycobacteriophage therapy.